Morley C J, Morley R
Department of Paediatrics, Addenbrooke's Hospital, Cambridge.
Arch Dis Child. 1990 Jul;65(7 Spec No):667-9. doi: 10.1136/adc.65.7_spec_no.667.
Of 235 survivors who had taken part in a randomised trial of artificial surfactant and who were born in Cambridge, follow up information was available for 231 (98%) infants. In 12 cases information came from local doctors; all others were assessed at 9 and 18 months (n = 212) or 9 months only (n = 7). There was no difference between those who had been treated with surfactant and control babies in the incidence of neurological impairment, mental impairment, respiratory infections, allergies, or hospital admissions up to 18 months after full term. In those born before 30 weeks' gestation (where surfactant most improves survival) the number of surviving randomised children who were normal was 35 of 61 in the treated group (57%) compared with 25 of 61 in the control group (41%). Improved neonatal survival after prophylactic surfactant treatment is not associated with an increased incidence of neurodevelopmental impairment.
在参与人工表面活性剂随机试验且出生于剑桥的235名幸存者中，有231名（98%）婴儿的随访信息可得。12例的信息来自当地医生；其他所有婴儿均在9个月和18个月时（n = 212）或仅在9个月时（n = 7）接受评估。在足月后18个月内，接受表面活性剂治疗的婴儿与对照婴儿在神经功能障碍、智力障碍、呼吸道感染、过敏或住院率方面没有差异。在妊娠30周前出生的婴儿中（表面活性剂对其生存改善最为明显），治疗组61名存活的随机分组儿童中有35名（57%）发育正常，而对照组61名中有25名（41%）发育正常。预防性表面活性剂治疗后新生儿存活率的提高与神经发育障碍发生率的增加无关。
